Evidence map›Paper›PMID 42003977›Full record

ArticleExploration of targeted anti-tumor therapy2026

Disrupting the TGF-β-regulated epithelial-mesenchymal transition, apoptotic and autophagic phenotypes of 3D glioblastoma spheroids via glycolytic inhibition.

Maellis Payet-Desruisseaux, Alain Zgheib, Bogdan Alexandru Danalache, Michel Desjarlais, Borhane Annabi

Abstract read
In one paragraph

Article in Exploration of targeted anti-tumor therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Maellis Payet-DesruisseauxLaboratoire d'Oncologie Moléculaire, Département de Chimie, Université du Québec à Montréal, Montreal, QC H3C 3P8, Canada.
Alain ZgheibLaboratoire d'Oncologie Moléculaire, Département de Chimie, Université du Québec à Montréal, Montreal, QC H3C 3P8, Canada.
Bogdan Alexandru DanalacheLaboratoire d'Oncologie Moléculaire, Département de Chimie, Université du Québec à Montréal, Montreal, QC H3C 3P8, Canada.ORCID https://orcid.org/0000-0003-1254-3689
Michel DesjarlaisHMR-RC, Université de Montréal, Montreal, QC H3T 1E2, Canada.ORCID https://orcid.org/0000-0002-5828-1760
Borhane AnnabiLaboratoire d'Oncologie Moléculaire, Département de Chimie, Université du Québec à Montréal, Montreal, QC H3C 3P8, Canada.ORCID https://orcid.org/0000-0002-5082-7183

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aim: Glioblastoma (GBM), a rare, highly aggressive and chemoresistant brain cancer, exhibits profound metabolic plasticity that relies, in part, on aberrant transforming growth factor-β (TGF-β) signaling. Such plasticity was recently associated with TGF-β-regulated apoptosis and autophagy. Here, we questioned whether TGF-β-regulated apoptotic/autophagic phenotypes are recapitulated in a preclinical in vitro 3D spheroid culture model of human U87 GBM-derived cells, and how metabolic alterations affect such phenotypes. Methods: 3D U87 spheroids were cultured using the hanging drop method. Western blotting was used to assess protein expression, while RT-qPCR was used to assess gene expression levels. Results: 3D spheroids exhibited decreased AKT phosphorylation, and increased TGF-β, fibronectin, and Smad2 phosphorylation, indicative of both cell death signaling and epithelial-mesenchymal transition molecular signatures. 2-Deoxy- Conclusions: 3D spheroids require ATP and a TGF-β/TGF-βR1 autocrine signaling axis to recapitulate the apoptosis/autophagy phenotypes. Combining glycolysis inhibition with TGF-β signaling inhibition could offer a promising therapeutic strategy for this rare and lethal brain cancer.

Indexed as

2-deoxy-D-glucoseapoptosisautophagyepithelial-to-mesenchymal transitionglioblastomaglycolytic inhibitionTGF-β

Identifiers

PMID42003977
PMCPMC13087734

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.